Salon Today
JULY 26, 2024
Jesse Kalsi transforms lives with his timeless wisdom about astronumerology and his groundbreaking method of number patching. His book empowers readers to manifest successful futures by harmonizing the energy in their lives using house numbers, birth dates, addresses, name numbers and more.
Dermatology Times
JULY 26, 2024
Along with the approval, Sun Pharma is introducing an access program to assist eligible patients in starting and adhering to the treatment.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Salon Today
JULY 26, 2024
The product offerings were specifically created to support natural curl patterns and textures and represents revolutionary curl innovation in-salon and at home.
Dermatology Times
JULY 26, 2024
Iltefat Hamzavi, MD, discusses the REGINA 007 phase 2 trial evaluating MK-6194 for the treatment of non-segmental vitiligo.
Mindbody
JULY 26, 2024
This month’s product updates include appointment optimizations, easy-to-sync branded web widgets, and more—changes that can help make the most of your software.
Dermatology Times
JULY 26, 2024
Combining electrocoagulation with pharmacotherapy significantly reduced keloid scar volume by inhibiting collagen deposition, angiogenesis, and cell proliferation.
Esthetician Leadership Today brings together the best content for skin care professionals from the widest variety of industry thought leaders.
Beauty Launchpad
JULY 26, 2024
MY SALON Suite announced it is offering 10 new $1,000 scholarship opportunities to help aspiring salon professionals achieve a license in cosmetology, barbering, esthetics, nail technology or massage therapy
Dermatology Times
JULY 26, 2024
In case you missed it, this week we had news about the FDA approval of deuruxolitinib for severe alopecia in adults, new nonmelanoma guidelines from the Dermatology Association of Radiation Therapy, Arcutis' submitted sNDA for roflumilast foam for scalp and body psoriasis, and more.
The Dermatology Digest
JULY 26, 2024
The U.S. Food and Drug Administration (FDA) has accepted for review Checkpoint’s resubmission of its Biologics License Application (BLA) for cosibelimab, its anti-programmed death ligand-1 (PD-L1) antibody, as a potential new treatment for adults with metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) who are not candidates for curative surgery or curative radiation.
Dermatology Times
JULY 26, 2024
Investigators looked into pollutant-induced disruption of the skin barrier, increased transepidermal water loss, and heightened inflammatory responses.
Dermatology Times
JULY 26, 2024
The lotion effectively rebalanced the microbiota, reduced erythema and desquamation, and improved acne severity.
Dermatology Times
JULY 26, 2024
A recent study found psoriasis content deemed “unreliable” still obtained 850,000 likes.
Expert insights. Personalized for you.
59 
Let's personalize your content